Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Papers

The ATSDR is committed for persons with ALS, caregivers, and researchers to read the latest scientific publications from the National ALS Registry and its partners. Many of the articles below are considered “Open Access” or available to read without a fee or subscription.

2018

New!

New!

  • Rechtman L, Jordan H, Kaye W, Ritsick M, & Mehta P. (2018). Increasing Patient Self-Enrollment in the National Amyotrophic Lateral Sclerosis Registry: Lessons Learned From a Direct to Provider Campaign. Journal of Patient Experience. https://doi.org/10.1177/2374373518811935

New!

  • Kullmann, J, A, P, Hayes, S, Pamphlett, R. Are people with amyotrophic lateral sclerosis (ALS) particularly nice? An international online case-control study of the Big Five personality factors. Brain and Behavior 2018, September 21: https://doi.org/10.1002/brb3.1119

New!

  • Kullmann, J, A, P, Hayes, S, Pamphlett, R. Is psychological stress a predisposing factor for amyotrophic lateral sclerosis (ALS)? An online international case-control study of premorbid life events, occupational stress, resilience and anxiety. PLOS One 2018, September 21: https://doi.org/10.1371/journal.pone.0204424

New!

2017

New!

  • Kuczmarski T, Stommel EW, Riley K, Tandan R, Chaudhry V, Clawson L, Caller TA, Henegan PL, Facciponte DN, Bradley WG, Andrew AS. Medical history of chemotherapy or immunosuppressive drug treatment reduces risk of amyotrophic lateral sclerosis (ALS). J Neurol, 2017; 264: 1763-1767. doi 10.1007/s00415-017-8564-2.

New!

  • Andrew AS, Caller TA, Tandan R, Duell EJ, Henegan PL, Field NC, Bradley WG, Stommel EW. Environmental and Occupational Exposures and Amyotrophic Lateral Sclerosis in New England. Neurodegener Dis. 2017; 17(2-3):110-6. PMCID: PMC5383428

 

 

 

New! 

 

 

 

 

 

 

 

 

 

2016

  • Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal Imaging in C9orf72 Mutation Carriers: Relationship to Phenotype. NeuroImage: Clinical 2016; 12:1035-1043. doi.org/10.1016/j.nicl.2016.10.014 

 

 

 

 

 

 

 

 

2015

Mehta P, Antao V, Horton K. Update on the United States National Amyotrophic Lateral Sclerosis (ALS) Registry. Amyotroph Lateral Sclerosis Frontotemporal Degener 2015 ; 16(Suppl. S1):146-159.

 

Kaye W, Wagner L, Mehta P. National Amyotrophic Lateral Sclerosis (ALS) Biorepository Feasibility Study. Amyotroph Lateral Scler Frontotemporal Degener 2015 ; 16(Suppl. S1):146-159.

 

Weisskopf M, Cudkowicz M, Johnson N. Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort. Epidemiology 2015 26(6). doi: 10.1097/EDE.0000000000000376.

 

Parkin A, Hayes S, Wang X, Pamphlett R. Designing an Internationally Accessible Web-Based Questionnaire to Discover Risk Factors for Amyotrophic Lateral Sclerosis: A Case-Control Study. JMIR Res Protoc 2015;4(3):e96 DOI: 0.2196/resprot.4840.

 

Oskarsson B, Horton DK, Mitsumoto H. Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Adobe PDF file Neurol Clin. 2015 Nov;33(4):877-88. doi: 10.1016/j.ncl.2015.07.009.

 

Roberts A, Johnson N, Cudkowicz M, Eum K, Weisskopf M. Job-related formaldehyde exposure and ALS mortality in the USA. J Neurol Neurosurg Psychiatry 2015. doi:10.1136/jnnp-2015-310750.

 

Rechtman L, Wagner L, Kaye W, Villanacci J. Updated Prevalence and Demographic Characteristics for ALS Cases in Texas, 2009–2011 .Southern Medical Journal 2015 108(8). doi: 10.14423/SMJ.0000000000000324.

 

Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, Kaye, W. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance .Amyotroph Lateral Scler Frontotemporal Degener 2015; Sep 23: 1-7. [Epub ahead of print].

 

Paulukonis ST, Roberts EM, Valle JP, Collins NN, English PB, Kaye WE. Survival and Cause of Death among a Cohort of Confirmed Amyotrophic Lateral Sclerosis Cases .LoS ONE 2015 10(7): e0131965. doi:10.1371/journal.pone.0131965.

 

Henry K, Fagliano J, Jordan H, Rechtman L, Kaye WE. Geographic Variation of Amyotrophic Lateral Sclerosis Incidence in New Jersey, 2009–2011 . Am. J. Epidemiol 2015; doi:10.1093/aje/kwv095.

 

Jordan H, Rechtman L, Wagner L, Kaye WE. Findings from the Baltimore and Philadelphia Amyotrophic Lateral Sclerosis Surveillance Projects, 2009-2011 .Muscle & Nerve 2015;51:815-821.

 

Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Muravov M, Horton D. Prevalence of Amyotrophic Lateral Sclerosis — United States, 2010–2011 .American Journal of Public Health: June 2015, Vol. 105, No. 6, pp. e7-e9.

 

Freer C, Hilton T, Jordan H, Kaye W, Singh S, Huang Y. 2015. Results of Florida’s Amyotrophic Lateral Sclerosis Surveillance Project .BMJ Open.‎ 2015;5:e007359doi:10.1136/bmjopen-2014-007359.

 

Valle J, Roberts E, Collins N, Paulukonis S, English P, Kaye W. Epidemiology and Surveillance of Amyotrophic Lateral Sclerosis in Two Large Metropolitan Areas in California .Amyotroph Lateral Scler Frontotemporal Degener 2015; Early Online: 1-7.

 

Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Effects of Demographic Factors on Survival Time after a Diagnosis of Amyotrophic Lateral Sclerosis .Neuroepidemiology 44:114-120.

2014

Rechtman L, Jordan H, Wagner L, Horton K, Kaye W. Racial and ethnic differences among Amyotrophic Lateral Sclerosis (ALS) cases in the United States .Amyotroph Lateral Scler Frontotemporal Degener 2014 Dec 8 [Epub ahead of print].

 

Jordan H, Rechtman L, Fagliano J, Lefkowitz D, Kaye W. Population-based Surveillance of Amyotrophic Lateral Sclerosis in New Jersey, 2009-2011 .Neuroepidemiology 43:49-56.

 

Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Muravov M, Horton D. Prevalence of Amyotrophic Lateral Sclerosis – United States, 2010-2011. Adobe PDF file MMWR Surveillance Summary 63(SS07);1-14.

 

Malek A, Stickler D, Antao VC, Horton DK. The National ALS Registry: a recruitment tool for research .Muscle Nerve 2014;50:830–834.

 

Horton K, Mehta P, Antao VC. Quantifying a nonnotifiable disease in the United States: the National Amyotrophic Lateral Sclerosis Registry model. JAMA 2014;312:1097–1098.

 

Yu Y, Su FC, Callaghan BC, Goutman SA, Batterman SA, Feldman EL. Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan .PLoS One. 2014 Jun 30;9(6):e101186. PMCID: PMC4076303.

 

Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States .Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:433–439.

2013

Factor-Litvak P, Al-Chalabi A, Ascherio A, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis .ALS Fronto Degen 2013;14(1):33-43.

 

Wittie M, Nelson LM, Usher S, Ward K, Benatar M. Utility of capture-recapture methodology to assess completeness of amyotrophic lateral sclerosis case ascertainment. Neuroepidemiology .2013;40(2):133-41.

 

Alexander V. Sherman, Amelie K. Gubitz, Ammar Al-Chalabi et al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis .Amyotrophic Lateral Sclerosis and Frontotemporal Degenerations 2013; 14(Suppl. 1): 53–61.

2012

2011

Stickler D, Royer J, Hardin J. Validity of hospital discharge data for identifying cases of amyotrophic lateral sclerosis .Muscle & Nerve 2011;44(5):814–815.

 

Benatar M, Wuu J, Usher S, Ward K. Preparing for a U.S. National ALS Registry: lessons from a pilot project in the State of Georgia .Amyotroph Lateral Scler 2011;12(2):130-135.

TOP